ASCO Connection

July 2017

Issue link:

Contents of this Issue


Page 2 of 67

Choose IMFINZI following platinum-based therapy for your patients with locally advanced or metastatic urothelial carcinoma. Visit Enable the immune system. RECOGNIZE. RESPOND. Effi cacy • 17.0% ORR among all patients (2.7% complete response, 14.3% partial response; n=182) 1 – 26.3% ORR among PD-L1 high expressers (n=95) 1 – 4.1% ORR among PD-L1 low/no expressers (n=73) 1 • 24.3% ORR demonstrated among patients who received only prior neoadjuvant or adjuvant therapy 1 • Median time to response was 6 weeks 2 – Based on a secondary endpoint in a single-arm trial • Median duration of response not yet reached 1 Safety • Serious potentially fatal risks were seen with IMFINZI; serious adverse reactions occurred in 46% of patients 1 • The most common Grade 3 or 4 adverse reactions were fatigue (6%), urinary tract infection (4%), musculoskeletal pain (4%), and abdominal pain (3%) 1 • The most common adverse reactions were fatigue (39%), musculoskeletal pain (24%), constipation (21%), decreased appetite (19%), and nausea (16%) 1 • Few discontinuations due to adverse events (3.3%) 1 ORR=objective response rate. ORR determined by blinded independent central review (BICR) of target lesion diameter according to RECIST v1.1 criteria. Important Safety Information There are no contraindications for IMFINZI ™ (durvalumab). Monitor patients for clinical signs and symptoms of immune-mediated pneumonitis, hepatitis, colitis or diarrhea, endocrinopathies, nephritis, rash or dermatitis, other immune-mediated adverse reactions, and infection. Please refer to the full Prescribing Information for important dose management information specifi c to adverse reactions. Please see Important Safety Information on next page.

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO Connection - July 2017